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The liver contains both NK cells and their less cytotoxic relatives, ILC1. Here,
we investigate the role of NK cells and ILC1 in the obesity-associated condition,
non-alcoholic fatty liver disease (NAFLD). In the livers of mice suffering from NAFLD,
NK cells are less able to degranulate, express lower levels of perforin and are less
able to kill cancerous target cells than those from healthy animals. This is associated
with a decreased ability to kill cancer cells in vivo. On the other hand, we find that
perforin-deficient mice suffer from less severe NAFLD, suggesting that this reduction
in NK cell cytotoxicity may be protective in the obese liver, albeit at the cost of increased
susceptibility to cancer. The decrease in cytotoxicity is associated with a shift toward a
transcriptional profile characteristic of ILC1, increased expression of the ILC1-associated
proteins CD200R1 and CD49a, and an altered metabolic profile mimicking that of ILC1.
We show that the conversion of NK cells to this less cytotoxic phenotype is at least
partially mediated by TGFβ, which is expressed at high levels in the obese liver. Finally,
we show that reduced cytotoxicity is also a feature of NK cells in the livers of human
NAFLD patients.
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INTRODUCTION
Natural killer (NK) cells are innate lymphoid cells that recognize and kill virally infected and
cancerous cells. In mice, NK cells were long defined as Lineage-negative NK1.1+. However, it
has recently come to light that, in tissues, cells defined in this way contain at least two distinct
populations: circulating, or conventional, NK cells that are CD49a−CD49b+ and tissue-resident
NK-like cells that are CD49a+CD49b− (1). These have been called either tissue-resident NK cells
or innate lymphoid cells, type 1 (ILC1): here, we call them ILC1 (2). A population of cells that
is in many ways equivalent to mouse tissue-resident CD49a+ NK cells is also present among
CD3−CD56+ cells in human livers and has been proposed to be ILC-like on the basis of its parallels
with mouse ILC1 (3). However, CD56− cells that display one of the proposed phenotypes for
human ILC1 (4) have also been reported in human liver (5). For this reason, here we refer to
the equivalent cells in humans by the descriptive term liver-resident NK cells. The finding that
Lin− NK1.1+ cells in mouse and CD3−CD56+ cells in human livers are in fact heterogeneous
populations means that it is now necessary to re-examine the roles of these cells, distinguishing
between NK and ILC1 or resident subpopulations.
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Non-alcoholic fatty liver disease (NAFLD) is a spectrum
of disease, usually associated with obesity, in which excess fat
builds up in the liver. Simple steatosis can progress to a chronic
inflammatory condition known as non-alcoholic steatohepatitis
(NASH). This in turn progresses to fibrosis and ultimately
cirrhosis, which increases the risk of developing hepatocellular
carcinoma. NASH patients have been reported to have increased
numbers of CD3−CD56+CD57+ cells, which are likely to
represent circulating NK cells, in their livers (6), although a
more recent study was unable to replicate this finding (7). The
expression of NK cell-activating ligands is also increased in the
livers of NASH patients. Recent findings on NK cell dysfunction
in obesity (8–11) and the metabolic activities of NK cells (12, 13)
have led to increased interest in a potential role for NK cells in
NAFLD pathogenesis but the field is still in its infancy, not least
because most previous studies did not distinguish between NK
cells and ILC1 or liver-resident NK cells (14).
NK cells can limit fibrosis in liver diseases of various etiologies
by controlling the activity of hepatic stellate cells (15, 16). In a
mouse study in which a NASH-like disease was induced using
a methionine and choline deficient diet, IFNγ production by
NKp46+ NK cells and ILC1 protected against disease (17). On
the other hand, NK cells seem to promote obesity, with NK cell-
deficient mice gaining less weight in response to obesogenic diets
(18–20) and displaying less fat accumulation and inflammation
in their livers (21). There is also evidence that NK cells can
be harmful in chronic inflammatory liver disease, where they
contribute to pathology by killing hepatocytes (22, 23). In support
of this being the case in NASH, mice lacking either TRAIL (an
apoptosis-inducing TNF family ligand expressed by NK cells)
or its receptor are partially protected against obesity-associated
NASH (24, 25).
Here, we investigate the activity of NK cells in a mouse model
of NASH and in the livers of NAFLD patients. We report that NK
cells in the livers of obese mice are less able to degranulate and
kill cancerous target cells than those from lean mice, a phenotype
that extends to a reduced in vivo ability to kill cancer cells. This
decrease in cytotoxicity is associated with a shift toward an ILC1-
like phenotype, which seems to be at least partially mediated by
high levels of TGFβ produced in the obese liver. Finally, we show
that in humans, as in mice, NK cells from obese livers are less able
to degranulate and kill.
RESULTS
NK Cells in the Livers of Obese Mice Are
Less Cytotoxic Than Those in the Livers of
Lean Mice
To investigate the activity of NK cells and ILC1 in the liver
during obesity-associated liver disease, we examined the spleens
and livers of mice that were kept for up to 24 weeks on a high
fat and sugar diet (26). As previously reported, mice on the
diet became obese (Supplementary Figure 1A), accumulated
fat in their livers (Supplementary Figure 1B) and displayed
dysregulated glucose homeostasis (Supplementary Figure 1C).
Mice also displayed histological evidence of NAFLD
(Supplementary Figures 1D,E) and increased circulating
alanine transaminase (ALT), which is an indicator of liver
damage (Supplementary Figure 1F).
We did not observe any difference in NK cell (defined as
Lineage-negative NK1.1+CD49a−CD49b+) or ILC1 (defined as
Lineage-negative NK1.1+CD49a+CD49b−) frequencies in the
spleens or livers of obese compared to lean mice (Figure 1A) but
NK cells isolated from the livers of mice that had been kept on the
obesogenic diet for 12 weeks degranulated less than those from
the livers of their lean littermates (Figure 1B). This was also the
case for NK cells isolated from spleens, although the reduction
was smaller (a difference in the medians of 4.3% in splenic
NK cells, compared to 10.0% in liver NK cells; Figure 1B). We
observed no difference in the degranulation of liver ILC1 between
lean and obese mice. We also found a significant reduction in
the expression of perforin by NK cells in the livers of obese
mice, that we did not detect in splenic NK cells (Figure 1C). This
suggests that NK cells from the livers of obese mice are both less
able to degranulate and less able to kill target cells than those
from their lean littermates. We did not observe any difference in
the expression of granzyme B (Figure 1D) although this may be
accounted for by the low levels at which this protein is expressed
in unstimulated mouse NK cells (27).
The reduced ability of NK cells in obese mice to degranulate
suggests that their ability to kill cancerous target cells will
be impaired. To determine whether this was the case, and to
examine the relative defects in NK cell killing in the spleens and
livers of obese compared to lean mice, we sorted NK cells from
the two organs and assessed their ability to kill YAC-1 cancerous
target cells in vitro. NK cells from both the spleens and livers of
obese mice were less able to kill YAC-1 cells than those from their
lean littermates, although the defect in killing was only significant
(at p < 0.05) in NK cells isolated from the liver (Figure 1E).
Similar to our observations of degranulation, the reduction in
target cell killing was greater in NK cells isolated from livers than
those isolated from spleens (a difference in the medians of 2.7%
in splenic NK cells, compared to 10.1% in liver NK cells).
To determine whether this affects target cell killing in vivo,
we next injected mice intravenously with equal numbers of
fluorescently-labeled RMA/s cells (which are MHC class I-
negative NK targets) and RMA cells (which are not NK targets
and act as a recovery control) (28). We collected spleens from the
recipient mice and determined the number of cells remaining in
each population by flow cytometry. The leanmice had eliminated
the RMA/s cells with approximately 40% efficiency. In contrast,




Clearly, the diminished ability of NK cells to kill target cells in
obese animals is likely to limit cancer surveillance. However,
since we observed the largest reductions in both degranulation
and cytotoxicity in NK cells isolated from the liver, and since the
reduction in perforin expression seemed to particularly affect NK
cells in the liver, we sought to define the likely effect of these
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FIGURE 1 | NK cells in the livers of obese mice are less cytotoxic than those in lean mice. (A) Immune cells were isolated from mouse livers. NK cells were identified
by scatter, and as live CD45+ Lineage-negative NK1.1+ CD49b+ cells. ILC1 were identified as live CD45+ Lineage-negative NK1.1+ CD49a+ cells. The frequency of
NK cells and ILC1 as a percentage of live CD45+ cells in the spleens and livers of lean and obese mice is shown. n = 12 mice per group, medians and IQRs are
shown. (B) Intrahepatic leukocytes were cultured for 4 h in the presence of anti-CD107a and Brefeldin A. Representative CD107a staining of NK cells from a lean (left,
blue) and an obese (right, red) mouse and summary data are shown. (C) Representative perforin staining in liver NK from a lean (blue trace) and an obese (red trace)
mouse. MFI of perforin in splenic NK, liver NK, and liver ILC1 from lean and obese mice are shown. (D) Representative granzyme B staining in liver NK from a lean
(blue trace) and an obese (red trace) mouse. Gray traces represent internal negative controls. MFI of granzyme B in splenic NK, liver NK, and liver ILC1 from lean and
obese mice are shown. (E) NK cells were sorted from the spleens and livers of lean and obese mice and cultured with the cancerous NK cell target line YAC-1. YAC-1
death at 24 h is shown. (F) CTV-labeled RMA/S (NK cell targets) CTB-labeled RMA (recovery control) cells were mixed in a 1:1 ratio and intravenously injected into
lean or obese mice. Representative input cells (leftmost, black) and recovered cells from lean (center, blue) and obese (rightmost, red) mice are shown. The
RMA/S:RMA ratio in recovered splenocytes, normalized to input ratio, is shown. For panels (B–F), n = 6 mice per group; significance was determined using Mann
Whitney U-Tests; medians and IQRs are shown.
changes in NAFLD. Given that TRAIL-mediated cytotoxicity
exacerbates NAFLD (24, 25), we speculated that there might be
some advantage to the reduced perforin-mediated cytotoxicity
we observed in the obese liver. We hypothesized that perforin-
mediated killing is harmful in the liver during obesity, and that
the reduction in NK cell degranulation, perforin expression and
Frontiers in Immunology | www.frontiersin.org 3 September 2019 | Volume 10 | Article 2180
Cuff et al. NK Become ILC1-Like in Obesity
cytotoxicity could therefore be protective. In this case, we would
expect mice lacking perforin to suffer less severe liver disease in
obesity. We therefore determined the extent of liver damage in
wild type and perforin-deficient mice that had been kept on the
obesogenic diet for 24 weeks. This later timepoint was chosen
so that we could compare the development of fibrosis, which is
not usually pronounced at 12 weeks in this model, between the
two genotypes.
There was no difference in weight gain (Figure 2A),
hepatomegaly (Figure 2B), or glucose homeostasis (Figure 2C)
between the wild type and perforin knockout mice. Therefore,
unlike mice that completely lack NK cells, perforin-deficient
mice gain weight and alter their glucose homeostasis similarly
to wild type mice (18–20). This suggests that any differences we
observe in liver pathology are unlikely to occur as a result of
less severe metabolic dysregulation in these mice. We observed
a significantly lower histopathological score in the perforin-
deficient mice than the wild type controls (Figures 2D,E) and
decreased circulating ALT, although this was not significant
at p < 0.05 (Figure 2F). Fibrosis, determined by Picrosirius
red staining, was significantly lower in perforin-deficient mice
(Figures 2D,G) and real time PCR for markers of fibrosis
revealed that the livers of the perforin-deficient mice expressed
less Acta2 (α smooth muscle actin; Figure 2H) and Col1a1
(collagen type I alpha 1; Figure 2I) than those of controls,
although the difference was only significant at p< 0.05 for Acta2.
NK Cells in the Livers of Obese Mice
Display a Transcriptional Profile
Characteristic of ILC1
We next sought to define the mechanism by which the reduction
in NK cell cytotoxicity occurs. To achieve this, we analyzed the
transcriptomes of NK cells and ILC1 in the livers of lean and
obese mice by RNASeq. Raw RNAseq data and differentially
expressed gene lists are available from the National Center for
Biotechnology Information Gene Expression Omnibus under
accession no. GSE122828; https://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE122828.
Only one gene, Malat1, was significantly (FC > 2, padj < 0.05)
underexpressed in NK cells from obese mice compared to those
from their lean littermates, whereas 20 genes were significantly
overexpressed. Of these 20 genes, 18 were also overexpressed
in ILC1 compared to NK cells (Figure 3A; genes characteristic
of ILC1 are marked with an asterisk). We particularly noted
that transcripts encoding the inhibitory receptors CD200R1,
LAG3, and CD101, all of which are involved in limiting immune
pathology in inflammatory diseases (29–32) were increased in
NK cells from obese mice compared to lean, as well as in
ILC1 compared to NK cells. We confirmed the increase in
expression at the protein level for CD200R1 (Figure 3B) and
LAG3 (Figure 3C). We also considered the possibility that a
decrease in activating receptor expression could account for the
decreased NK cell activity in obese mice, but we did not find any
difference in NKG2D (Supplementary Figure 2A) and NKp46
(Supplementary Figure 2B) levels between NK cells from lean
and obese mice.
NK cells and ILC1 express the transcription factor Tbet at
roughly similar levels, although they rely on it to different extents
(33–37). Consistent with this, we did not detect any change in
the expression of Tbet in NK cells of the livers of lean compared
to obese mice (Supplementary Figure 2C). On the other hand,
the transcription factor Eomes is expressed only by NK cells
and specifies the NK cell lineage (38). We observed decreased
expression of Eomes in NK cells in the livers of obese compared
to leanmice (Figure 3D).We also examined the expression of the
ILC1-associated integrin CD49a and found a small but significant
increase in its expression by NK cells in the livers of obese
compared to lean animals (Figure 3E), consistent with a shift
towards an ILC1-like phenotype.
NK Cells in the Livers of Obese Mice Have
an Altered Metabolic Profile
Gene Ontology analysis on this relatively short list of
differentially expressed transcripts (Figure 3A) revealed that
only one pathway was significantly overrepresented in the NK
cells of obese mice, compared to lean littermates, and this was
Triglyceride catabolic processes (p= 3.65× 10−3). We therefore
examined the cells for signs of altered immunometabolism.
Scatter has been used as an indicator of metabolic alteration
in NK cells (39) and we found that side scatter increased in NK
cells from the livers of obese mice (Figure 4A). NK cells use
mTOR for nutrient sensing and it also has an important role in
immune regulation (40). The phosphorylation of ribosomal S6
protein (pS6) is used as an indicator of mTORC1 signaling and
we found that pS6 was increased in NK cells freshly isolated from
the livers of obese compared to lean mice (Figure 4B). Notably,
in both these cases, the metabolic alterations that we observed in
the NK cells served to make them more ILC1-like, similar to our
findings at the transcriptional level. We also observed an increase
in the expression of the glucose transporter Glut1 (Figure 4C).
TGFβ in the Obese Liver Limits NK Cell
Degranulation and Alters Their Metabolic
Profile
The conversion of NK cells to a less cytotoxic ILC1-like
phenotype has previously been reported in a number of situations
and in all these cases, TGFβ was a key cytokine driving the
conversion (41–43). We therefore hypothesized that TGFβ in
the obese liver might be mediating the reduction in cytotoxic
ability and the acquisition of ILC1-like features that we observed.
Tgfb1 transcript was increased in the livers of obese compared
to lean mice (Figure 5A) and we also observed increased TGFβ1
protein in conditioned medium from obese compared to lean
livers (Figure 5B) and in the plasma of obese mice (Figure 5C).
NK cells move freely between the periphery and the liver (37).
In order to define how the profile of NK cells might alter as
they enter the liver, and how this might differ depending on the
NAFLD status of the liver, we isolated splenic NK cells from lean
animals and cultured them for 24 h in conditioned medium from
either lean or obese mouse livers. We observed that the ability of
NK cells to degranulate was impaired following culture in obese,
compared to lean, liver conditioned medium, and we were also
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FIGURE 2 | Perforin-mediated killing promotes fibrosis in NAFLD. (A) Growth curves for wild type and perforin knockout mice on the obesogenic diet. (B) Liver
weights for wild type and perforin knockout mice after 24 weeks on the obesogenic diet. (C) Plasma glucose levels. (D) Representative H&E and Picrosirius red
staining in a wild type and a perforin knockout mouse. (E) Histological score in wild type and perforin knockout mouse livers, after 24 weeks on the obesogenic diet.
(F) Plasma ALT levels. (G) Picrosirius red positive area in representative histological fields. (H,I) Acta2 and Col1a1 mRNA in livers of wild type and perforin knockout
mice, after 24 weeks on the obesogenic diet. n = 8 mice per group; significance was determined using Mann Whitney U-Tests; medians and IQRs are shown.
able to recapitulate this phenotype by culturing the NK cells in
recombinant TGFβ1 (Figure 5D). Furthermore, the addition of
an anti-pan TGFβ antibody to the cultures partially rescued the
ability of the NK cells to degranulate following culture with obese
liver conditioned medium (Figure 5E), suggesting that TGFβ
in the obese liver limits the ability of NK cells to degranulate.
We also examined pS6 expression as an indicator of mTORC
signaling. Consistent with previous reports, NK cells cultured
with TGFβ1 displayed reduced pS6 (12), as did NK cells cultured
in obese liver conditioned medium (Figure 5F), suggesting that
TGFβ in the obese liver can also affect the metabolic profile of
NK cells.
Consistent with previous reports (42), NK cells cultured for
5 days in TGFβ1 upregulated ILC1-associated molecules such
as CD49a (Figure 5G) and CD200R1 (Figure 5H). However,
we did not observe this phenomenon in NK cells cultured
for only 24 h in TGFβ1 and we were unable to keep
NK cells alive in liver conditioned medium for 5 days.
Therefore, we were unable to directly assess the ability of
liver conditioned medium to convert NK cells to ILC1.
Our findings that the obese liver contains high levels of
TGFβ1 and that TGFβ can convert NK cells to an ILC1-
like phenotype does, however, suggest that this could occur
in vivo.
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FIGURE 3 | NK cells in the livers of obese mice acquire an ILC1-like transcriptional profile. (A) NK cells and ILC1 were sorted from the livers of lean and obese mice
and examined by RNASeq. Genes that were differentially expressed by >2-fold, with padj <0.05, in NK cells of lean vs. obese mice are shown. Genes that are also
differentially expressed in ILC1 compared to NK (>2-fold, with padj <0.05) are marked with an asterisk. (B,C) Protein expression of the inhibitory receptors CD200R1
(B) and LAG3 (C) in NK cells and ILC1 of lean (blue) compared to obese (red) mice. Gray traces represent FMO controls. (D) Expression of Eomes in NK cells and
ILC1 of lean (blue) compared to obese (red) mice. Gray traces represent internal negative controls. (E) Expression of CD49a in Lineage-negative NK1.1+ CD49b+
cells (NK) and Lineage-negative NK1.1+ CD49b− cells (ILC1) of lean (blue) compared to obese (red) mice. Gray traces represent FMO controls. n = 6 mice per group;
significance was determined using Mann Whitney U-Tests; medians and IQRs are shown.
NK Cells in the Livers of NAFLD Patients
Are Less Cytotoxic Than Those From
Healthy Controls
Our observations in mice prompted us to ask whether NK
cells in the livers of NAFLD and NASH patients are also
less able to degranulate than those from healthy controls. We
isolated intrahepatic leukocytes from seven healthy livers, six
livers with simple steatosis (livers that showed steatosis but
no inflammation) and six livers displaying various levels of
inflammation and fibrosis in addition to steatosis. We found
the ability of NK cells [defined as CD3−CD56+Tbethi Eomeslo;
(41); Figure 6A] to degranulate was inversely correlated with
disease severity (Figures 6B–D). In seven samples where we
were also able to sort the NK cells and assess their ability to
kill the classical human NK cell target line K562, we found
decreased killing by NK cells from NAFLD livers compared to
healthy controls, although we were not able to collect enough
data points to robustly assess the statistical significance of this
relationship (Figure 6E). Interestingly, we found that the ability
of liver-resident NK cells to degranulate was also inversely
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FIGURE 4 | NK cells in the livers of obese mice are metabolically reprogrammed. Forward and side scatter (A), pS6 staining (B), and Glut1 staining (C) of freshly
isolated NK cells and ILC1 from lean (blue) and obese (red) mice. n = 12 mice per group (A), six mice per group (B) and seven mice per group (C); significance was
determined using Mann Whitney U-Tests; medians and IQRs are shown.
correlated with disease severity, although less significantly than
that of circulating NK cells (Figure 6F). However, in contrast
to the situation for circulating NK cells, we did not observe
decreased cytotoxicity in liver-resident NK cells from NAFLD
patients, compared to healthy controls (Figure 6G). This is in
line with our previous observation that degranulation is not
particularly correlated with cytotoxicity in human liver-resident
NK cells (41).
DISCUSSION
It is becoming increasingly apparent that NK cells are
dysfunctional in obesity and that this could be one mechanism
that accounts for the well-established link between obesity and
cancer (8–11). These studies have largely focused on NK cells
in the blood, but in this study we looked at how NK cells
in the liver change during obesity and the impact that this
may have not only on cancer immunosurveillance, but also on
NAFLD pathogenesis.
We found that in obesity NK cells in the livers of both humans
and mice are less able to degranulate and kill target cells. This
is consistent with reports that NK cells taken from the blood of
obese humans (8–10, 44) or the spleens of obese mice (10) are
less cytotoxic than those taken from their lean counterparts. On
the other hand, one recent study did not find a reduction in NK
cell degranulation in the blood of NAFLD patients compared to
controls (7). This study also found no association between NK
cell phenotype in the liver and NAFLD severity, although it did
not examine degranulation or cytotoxicity. In the light of our
findings in mice, that the obesity-associated defect in NK cell
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FIGURE 5 | TGFβ in obese mouse livers limits NK cell degranulation and alters their metabolic profile. (A) Tgfb1 mRNA in the livers of lean and obese mice,
normalized so that mean Tgfb1 transcript expression in the livers of lean mice = 1. (B,C) TGFβ1 in lean and obese liver conditioned medium (B) and lean and obese
(Continued)
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FIGURE 5 | mouse plasma (C) measured by ELISA. n = 8 mice per group (A,C) and six conditioned media per group (B); significance was determined using Mann
Whitney U-Tests; medians and IQRs are shown. (D) Splenic NK cells were cultured for 24 h in medium alone, lean or obese liver conditioned medium, or 10 ng/ml
TGFβ1. For the last 4 h of culture, CD107a antibody and Brefeldin A were added to media. n = 6 culture conditions per group; significance was determined using
Mann Whitney U-Tests with Holm’s correction for multiple comparisons; medians and IQRs are shown. (E) Splenic NK cells were cultured as described in (D), with the
addition of 10µg/ml anti-TGFβ antibody or isotype control. n = 6 culture conditions per group; significance was determined using a Wilcoxon signed ranks test,
where each pair is obese liver conditioned medium from the same mouse, with anti-TGFβ antibody or isotype control. Degranulation in NK cells cultured in lean liver
conditioned medium with isotype control are shown for comparison, but were not statistically tested. (F) Splenic NK cells were cultured for 24 h in medium alone, lean
or obese liver conditioned medium, or 10 ng/ml TGFβ1, before staining for pS6. n = 6 culture conditions per group; significance was determined using Mann Whitney
U-Tests with Holm’s correction for multiple comparisons; medians and IQRs are shown. (G,H) Splenic NK cells were cultured for 5 d in 10 ng/ml TGFβ1. CD49a (G)
and CD200R (H) staining before and after culture are shown. For this small dataset, no statistical testing was carried out.
degranulation and killing is more marked in the liver than the
periphery, one possibility is that a defect in NK cytotoxicity does
exist in this cohort but, as we report here, it is necessary to look
in the liver to find it.
We further show that the NK cells of obese mice are less
able to kill cancerous target cells in vivo. It has recently been
reported that NK cells that have been cultured in fatty acids
before being adoptively transferred into a B16melanoma-bearing
host are less able to control the cancer than control NK cells.
Obese mice are also less able to control B16 metastases than their
lean counterparts, a phenotype that was associated with reduced
NK cell infiltration into metastatic foci (10). Our finding that
obese mice are less able to control RMA/S cells confirms these
findings using a second type of cancerous target.
This reduction in NK cell cytotoxicity in obesity is detrimental
to tumor immunosurveillance, but one key question is whether
it is helpful or harmful in the context of NAFLD. We observed
greater reductions in degranulation, perforin expression, and
cytotoxicity in the liver than in the spleen. Further, TRAIL-
mediated cytotoxicity is known to promote pathogenesis in
NAFLD (24, 25). Therefore, we postulated that the decrease
in degranulation and perforin-mediated cytotoxicity that we
observed in the obese liver might protect against liver disease.
In support of this idea, perforin-deficient mice suffered from less
severe NAFLD. Since these animals lack perforin globally, we
cannot say with certainty that the protection is not mediated
at least in part by defective T cell cytotoxicity. Indeed if,
as we suggest, the liver is acting to protect itself against
immunopathology, it is likely that T cell cytotoxicity will also be
reduced. Nevertheless, the protection from liver disease that we
find in the absence of perforin does suggest that the defect in
NK cell degranulation we observe in the obese liver may act to
protect it.
We found the genes differentially expressed between NK cells
from lean vs. obese livers to be strikingly similar to those that are
differentially expressed between NK cells and ILC1, suggesting
NK cell conversion to an ILC1-like phenotype in the obese liver.
In support of this idea, we found the ILC1-associated proteins
CD200R1 (45), LAG3, and CD49a increased in NK cells from
obese livers, and expression of the NK cell lineage-defining
transcription factor Eomes decreased. NK cells in the livers of
obese mice also displayed an altered metabolic profile, which was
somewhat like that of ILC1.
There are a number of situations in which NK cells are
converted to resident or ILC1-like cells and in some of these,
notably in the tumor microenvironment, this is associated with
a decrease in cytotoxicity similar to our findings in the obese
liver (41–43). NK to ILC1 conversion in all these situations is
mediated by TGFβ. Further, TGFβ is known to alter themetabolic
profile of NK cells and limit their cytotoxicity (8, 13). Therefore,
we postulated that NK cell acquisition of an ILC1-like phenotype
in the obese liver might be mediated by TGFβ. TGFβ levels
were higher in obese than lean livers, consistent with previous
reports in both mice and humans (46–48). Conditioned medium
from obese livers limited the ability of NK cells to degranulate,
mirroring the phenotype observed in the obese liver, and this
effect was TGFβ-dependent. We also assessed the effect of liver
conditioned medium on mTORC1 signaling, as determined by
pS6 levels, and again observed obese liver conditioned medium
mimicking the effect of TGFβ (12).
Interestingly, we observed reduced pS6 levels on short term
culture with either obese liver conditioned medium or TGFβ but
increased pS6 levels in the livers of mice that had been kept on the
obesogenic diet for 6 months. It has previously been suggested
that there may be differences in the kinetics of altered mTORC1
signaling in short-term vs. longer-term TGFβ exposure, and this
may be at play here (13). In support of this idea, the short- and
long-term effects of obesity on NK cell metabolism are known to
differ: in a pediatric cohort, obesity was associated with increased
Glut1 and pS6 expression (9), whereas in adults, obesity was
associated with decreased 2-NBDG uptake (a proxy for glucose
uptake) and pS6 expression (10). It is also likely to be the case
that other factors present in the obese liver, for example high
levels of fatty acids, affect NK cell cytotoxicity and metabolism
(10), and the effects of these may interact with TGFβ, possibly in
a manner which changes over time. This could also explain our
observation that obese liver conditioned medium depresses NK
cell pS6 expression more than TGFβ alone.
In this study, we have shown that NK cells in the liver display
a less cytotoxic ILC1-like phenotype in the context of obesity
and that this is likely to be at least partially TGFβ-mediated.
Our finding that perforin-mediated killing is harmful in NAFLD
suggests that this reduction in NK cell cytotoxicity is protective
in the liver, albeit at the cost of increased susceptibility to cancer.
As well as mediating conversion of NK cells to ILC1 (41–43),
TGFβ also alters NK cell metabolism and cytotoxicity (8, 13). It
has recently been suggested that NK cell metabolism could be
targeted to prevent cancer (40). In the light of recent findings
that NK cells are less cytotoxic in obesity and that this is at least
partially mediated by metabolic changes (8–10, 44), it might be
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FIGURE 6 | NK cells in the livers of NAFLD patients are less cytotoxic than those from healthy controls. (A) Immune cells were isolated from human livers. NK cells
were identified by scatter, and as live CD45+ CD56+ CD3− Tbethi Eomeslo cells. Liver-resident NK cells (lrNK) were identified as live CD45+ CD56+ CD3− Tbetlo
(Continued)
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FIGURE 6 | Eomeshi cells. (B,C) Intrahepatic leukocytes were cultured for 4 h in the presence of anti-CD107a and Brefeldin A. Representative CD107a staining of NK
cells from a healthy (B) and a NAFLD (C) liver is shown. (D) Inverse correlation between NK cell degranulation and histological score in human livers. H, healthy; SS,
simple steatosis; NAS, NASH Activity Score; C, cirrhosis. Significance was determined using Spearman’s Rank Correlation. (E) CD56+ CD3− CD16+ CXCR6− NK
cells were sorted from healthy (n = 4) and NAFLD (n = 3) livers and cultured for 4 h with the human NK target cell, K562. At the end of culture, target cell death was
assessed using AnnexinV staining. (F) Inverse correlation between liver-resident NK cell degranulation and histological score in human livers. Significance was
determined using Spearman’s Rank Correlation. (G) CD56+ CD3− CXCR6+ liver-resident NK cells were sorted from healthy (n = 4) and NAFLD (n = 3) livers and
cultured for 4 h with the human NK target cell, K562. At the end of culture, target cell death was assessed using AnnexinV staining. For (E,G), medians are shown. For
these small datasets, no statistical testing was carried out.
tempting to consider using such treatments as a way to break the
well-established link between cancer and obesity (49). However,
the implication that reduced NK cell cytotoxicity may protect
the liver during obesity sounds a note of caution about such
approaches, which may result in adverse effects in the liver.
Indeed, NK cell-derived ILC1-like cells play a role in tissue repair
(42) so the possibility that the ILC1-like cells we see emerging
from NK cells in the obese liver may even have a reparative effect
is worthy of further investigation.
MATERIALS AND METHODS
Human Liver Biopsies
Liver biopsies were taken from livers that were destined for
transplantation, but that were discarded because of long warm
ischemic time, vascular abnormalities, or tumors elsewhere in
the patient (n = 7), or because they displayed signs of NAFLD
or NASH on histopathologic examination (n = 10). Biopsies
were also taken from livers explanted during transplantation
for NASH (n = 2). Intrahepatic leukocytes were isolated as
previously described (41). Briefly, liver tissue was finely minced
using scalpels, passed through a 70-µm strainer, and the collected
cells were layered onto Ficoll (GE Healthcare, Amersham,
U.K), centrifuged (400 × g, 20min, 20◦C, light braking), and
the interface was taken and washed twice with PBS (750 ×
g, 15min, 20◦C). Ethical approval for use of human liver
samples was obtained through the Royal Free Hospital Biobank
(National Health Service Research Ethics Committee approval
no. 11/WA/0077, study no. 9455).
Mice
Female C57BL/6J (bred in house) or Prf1−/− mice (Charles
River; RRID:MGI:5576721) were randomized at weaning onto
standard chow (RM1) or a highly palatable obesogenic diet
consisting of 22.6% fat, 23.0% protein, and 40.2% carbohydrate
(w/w); diet code 824018—“45%AFE fat” Special Dietary Services,
Essex, UK), supplemented with sweetened condensed milk
(Nestle) ad libitum (26).
After 12 or 24 weeks on the diet, mice were sacrificed by direct
cervical dislocation. Blood was collected by cardiac puncture and
centrifuged at 10,000 × g for 10min at room temperature to
isolate serum for ALT and glucose measurement and pieces of
liver were fixed in 10% neutral buffered formalin, fixed, sectioned,
and stained with H& E or Picrosirius red. Sections were blinded
and scored by a hepatopathologist, using the Brunt-Kleiner
NASH activity score [NAS; (50)]. Spleens were collected and
splenocytes isolated as previously described (51). Intrahepatic
lymphocytes were isolated using an adaptation of the method
from Cuff and Male (51). Briefly, finely minced liver tissue
was collected in RPMI 1640 medium (Life Technologies brand;
Thermo Fisher Scientific, Hudson, NH) and passed through
a 70µm cell strainer. The suspension was spun down (500
× g, 4◦C, 10min) and the pellet resuspended in RPMI 1640
medium. The cell suspension was layered over 24% Optiprep
(Sigma-Aldrich) and centrifuged without braking (700 × g, RT,
20min). The interface layer was taken and washed in HBSS
without Ca2+ Mg2+ (Lonza, distributed by VWR, Lutterworth,
UK) supplemented with 0.25% bovine serum albumin (Sigma-
Aldrich, Hammerhill, U.K) and 0.001% DNase I (Roche,
distributed by Sigma-Aldrich).
Animal husbandry and experimental procedures were
performed according to UK Home Office regulations and
institute guidelines, under project license 70/8530.
In vivo NK Cytotoxicity Assays
RMA and RMA/s thymoma cells (cultured in Iscove’s
modified Dulbecco’s medium supplemented with 10% FCS;
Life Technologies) were labeled with Cell Trace Blue or Cell
Trace Violet, respectively, according to the manufacturer’s
instructions (Thermo Fisher Scientific). 107 cells of each cell type
were injected intravenously into control or obese mice. After 4 h,
recipients were sacrificed by direct cervical dislocation and the
spleens were examined for fluorescent target cells.
Ex vivo NK Cell Activity Assays
For degranulation assays using mouse NK cells, total intrahepatic
leukocytes or splenocytes were cultured for 4 h at 107
cells/mL in RPMI 1640 medium supplemented with 10% FCS,
25mM HEPES, 1mM sodium pyruvate, 50µM 2-ME, MEM
nonessential amino acids, penicillin, and streptomycin (all Life
Technologies brand; Thermo Fisher Scientific, Waltham, MA,
USA). Brefeldin A (1µg/mL; Sigma-Aldrich) and anti-CD107a
(1:100, eBioscience, San Diego, CA) were added to all conditions.
For cytotoxicity assays, 15,000 sorted NK cells were cultured
with 75,000 YAC-1 target cells in 100 µL RPMI supplemented
as before for 24 h. Cell death was measured using an LDH
cytotoxicity assay (Abcam, Cambridge, U.K.), according to the
manufacturer’s instructions. Readings were normalized between
the medium only (0% cell death) and lysis buffer (100% cell
death) controls.
Degranulation and cytotoxicity assays with human NK
cells were carried out as previously described (41). Briefly,
freshly isolated intrahepatic lymphocytes were cultured for 4 h
with Brefeldin A (10µg/ml; Sigma-Aldrich), Monensin (2µM;
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TABLE 1 | Details of antibodies used in the study.
Antibody Clone Fluorophore Dil Host animal Manufacturer Catalog # RRID
Anti-human CD3 SK7 APC-eFluor 780 1/200 Mouse eBioscience 47-0036-42 AB_10717514
Anti-human CD45 HI30 PE 1/100 Mouse eBioscience 12-0459 AB_1944374
Anti-human CD56 NCAM16.2 Brilliant Violet 510 1/200 Mouse BD Biosciences 563041 AB_2732786
Anti-human CD107 eBioH4A3 PerCP-eFluor 710 1/100 Mouse eBioscience 46-1079-42 AB_2573706
Anti-human Eomes WD1928 PE-eFluor 610 1/100 Mouse eBioscience 61-4877-42 AB_2574616
Anti-human/mouse Tbet eBio4B10 PE-Cy7 1/100 Mouse eBioscience 25-5825-82 AB_11042699
Anti-mouse CD3 17A2 FITC 1/200 Rat Biolegend 100203 AB_312660
Anti-mouse CD3 17A2 PerCP-Cy5.5 1/200 Rat Biolegend 100218 AB_1595492
Anti-mouse CD8α 53-6.7 FITC 1/200 Rat Biolegend 100705 AB_312744
Anti-mouse CD8α 53-6.7 PerCP-Cy5.5 1/200 Rat Biolegend 100734 AB_2075238
Anti-mouse CD19 6D5 FITC 1/200 Rat Biolegend 115505 AB_313640
Anti-mouse CD19 6D5 PerCP-Cy5.5 1/200 Rat Biolegend 115534 AB_2072925
Anti-mouse CD45 30-F11 Brilliant Violet 510 1/200 Rat Biolegend 103137 AB_2561392
Anti-mouse/rat CD49a Ha31/8 Alexa Fluor 647 1/100 Armenian hampster BD Biosciences 562113 AB_11153312
Anti-mouse/rat CD49a Ha31/8 BUV 395 1/200 Armenian hampster BD Biosciences 740262 AB_2740005
Anti-mouse CD49b DX5 PerCP-eFluor 710 1/200 Rat eBioscience 46-5971 AB_11149865
Anti-mouse CD49b DX5 PE-eFluor 610 1/200 Rat eBioscience 61-5971-80 AB_2574645
Anti-mouse CD107a 1D4B PE-Cy7 1/100 Rat Biolegend 121620 AB_2562147
Anti-mouse CD200R1 OX-110 PE 1/50 Rat BioLegend 123907 AB_2074081
Anti-mouse Eomes Dan11mag PE-Cy7 1/100 Rat eBioscience 25-4875 AB_2573453
Anti-mouse/rat/human Glut1 EPR3915 Alexa Fluor 647 1/100 Rabbit abcam ab195020 AB_2783877
Anti-mouse Gr-1 RB6-8C5 FITC 1/200 Rat Biolegend 108405 AB_313370
Anti-mouse Gr-1 RB6-8C5 PerCP-Cy5.5 1/200 Rat Biolegend 108428 AB_893558
Anti-mouse Lag3 C9B7W PE/Dazzle 594 1/100 Rat Biolegend 125223 AB_2572081
Anti-mouse NK1.1 PK136 APC-eFluor 780 1/100 Mouse eBioscience 47-5941 AB_10853969
Anti-mouse Perforin S16009B PE 1/50 Rat Biolegend 154405 AB_2721640
Anti-mouse pS6 D57.2.2E APC 1/50 Rabbit Cell Signaling 4858 AB_916156
Sigma-Aldrich), and 5 ng/ml PerCP–eFluor 710-conjugated
anti-human CD107a (clone eBioH4A3; eBioscience). Cell
surface staining was performed at the end of the assay.
For cytotoxicity assays, sorted cells were cultured with K562
for 4 h at a 1:1 ratio in 50 µl of RPMI 1640 medium
supplemented as above. At the end of the assay, target cell
death was assessed using Annexin V-FITC (BD Biosciences) and
propidium iodide.
Cell Culture Experiments
Liver conditioned medium was produced by culturing 500mg
of finely minced liver tissue in serum-free M199 medium
(Gibco brand, Thermo Fisher Scientific) for 48 h. The medium
was cleared of debris by being passed through a 70µm
strainer and by centrifugation at 500 × g for 5min at
4◦C. Splenic NK cells were cultured for 24 h in RPMI
supplemented as before mixed 3:1 with liver conditioned
medium or unconditioned M199 medium. TGFβ1 (10 ng/mL,
PeproTech, Rocky Hill, NJ), anti-mouse TGFβ (10µg/mL, clone
1D11 R&D Systems, Minneapolis, MN) or isotype control
antibody (10µg/mL, clone 11711 R&D Systems) were added
as indicated.
Flow Cytometry
Details of antibodies used in the study are given in Table 1.
The lineage cocktail for mouse cells consisted of CD3, CD8α,
CD19, and Gr1. Dead cells were excluded using fixable viability
dye eFluor 450 (eBioscience) (4◦C, 15min). Surface staining
was carried out in PBS supplemented with 1% FCS (4◦C,
15min). Intracellular staining was carried out using Human
FoxP3 Buffer (BD Biosciences, Oxford, UK), except for pS6
staining, which was carried out using Cytofix/cytoperm (BD
Biosciences). Data were acquired on an LSRFortessa II (BD
Biosciences) and analyzed using FlowJo v.X.0.7 (Tree Star,
Ashland, OR, USA). Sorting was carried out on an Aria
(BD Biosciences).
Real Time PCR
Liver sections were dissected directly into RNAlater and RNA
was extracted using an RNeasy Lipid Tissue Mini kit (both from
Qiagen, Manchester, U.K.). cDNAwasmade using a Transcriptor
First Strand cDNA Synthesis kit (Roche, Welwyn Garden City,
U.K.) and real-time PCR was performed using TaqMan (Applied
Biosystems, Warrington, U.K.) primer/probe sets recognizing
Hprt1 (Mm00446968_m1), Acta2 (Mm01546133_m1), Col1a1
(Mm00801666_g1), and Tgfb1 (Mm01178820_m1).
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RNASeq
Total RNA was extracted from sorted cells using an RNeasy
Micro kit (Qiagen) and libraries were prepared from 2
ng of total RNA using the NEBNext low input kit (New
England Biolabs, Hitchen, U.K.). Libraries were assessed for
correct size distribution on the Agilent 2200 TapeStation and
quantified by Qubit DNA High Sensitivity assay (Thermo
Fisher Scientific) before being pooled at an equimolar
concentration. Samples were sequenced on a NextSeq 500
(Illumina, Essex, U.K). Differential expression analysis was
carried out using SARTools (52), filtering at padj <0.05
and FC > 2.
TGFβ1 ELISA
Total TGFβ1 protein concentrations in plasma and liver
conditioned medium were determined using a mouse
TGF-beta1 DuoSet ELISA (R&D Systems), according to the
manufacturer’s instructions.
Statistics
The data was analyzed and found not to be normally distributed.
Significance was therefore determined using non-parametric
tests: Mann Whitney U-Tests (for unpaired data), Wilcoxon
signed rank tests (for paired data) or Spearman’s tests (for
correlations) as indicated in the figure legends. P-values < 0.05
are reported. Bars represent medians and interquartile ranges;
individual data points are also plotted.
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Supplementary Figure 1 | Mice fed an obesogenic diet develop fatty liver
disease. (A) Growth curves for mice fed an obesogenic diet (red) or standard
chow (blue). (B) Liver weights at 3 (n = 12 mice/group) or 6 months (n = 8 mice in
the lean and seven mice in the obese group). (C) Plasma glucose levels (n = 8
mice per group, except for obese at 6 months where n = 7 mice). (D) H&E and
Picrosirius red staining in representative livers after 3 months on the obesogenic or
standard diet. (E) Histological scores (n = 12 mice per group at 3 months, eight
lean mice at 6 months and seven obese mice at 6 months). (F) Plasma ALT levels
(n = 12 mice per group at 3 months, eight lean mice at 6 months and seven
obese mice at 6 months). Significance was determined using Mann Whitney
U-Tests; medians and IQRs are shown.
Supplementary Figure 2 | No difference in NKG2D, NKp46, or Tbet expression
in NK cells from lean vs. obese mice. NKG2D (A), NKp46 (B), and Tbet staining
(C) of freshly isolated NK cells and ILC1 from lean (blue) and obese (red) mice.
Gray traces represent internal negative controls (A–C). n = 6 mice per group;
significance was determined using Mann Whitney U-Tests; medians and IQRs
are shown.
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